The number to beat is 39%CR...(for now).We all know that the Big Pharma that will strike a deal with TLT for TLT-Ruvidar will use the "Optimized Treatment Protocol CR%" to evaluate TLT treatment potential and value($).
If you read the last email from Matthew Perraton...Under " FDA Approved Drugs Versus Ruvidar"(blue box).
TLT said" Theralase Ruvidar estimated durable CR%(15 months) for 2026 is 39% optimized".
Note..For me 39%CR in 2026 seem to be concervative(but what do I know).
As we speak TLT-Ruvidar 15 months CR% is 36%CR optimized(36%CR is already huge if you consider that TLT-Ruvidar treat patients that other treatments can't treat).
Valrubicin, Keytruda,Adstiladrin, N803+BCG...All the above have long term CR% lower than 39%, and have either side effects(Valrubicin,Keytruda) or many restrictions(Adstiladrin,N803+BCG).
As we speak TLT-Ruvidar is the only treatment that doesn't have side effect or restrictions and a 36-39%CR.
In short TLT-Ruvidar is the only treatment that will treat 100% of patients.
Question???
What is the $value of a Big Pharma deal for a treatment that has 36-39CR% no side effects and no restrictions and can treat 100% of patients?
We are on the verge of finding out.